Merck (MRK) Depreciation and Depletion (2020 - 2026)
Merck (MRK) reported Depreciation and Depletion of $581.0 million for Q1 2026, up 15.74% year-over-year from $502.0 million in Q1 2025, and down 61.09% quarter-over-quarter from $1.5 billion in Q4 2025.
Merck (MRK) Depreciation and Depletion (2020 - 2026) Analysis & Trends
Merck (MRK) has 7 years of Depreciation and Depletion data on file, last reported at $581.0 million in Q1 2026.
- Depreciation and Depletion for Q1 2026 came in at $581.0 million, up 15.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 115.87% YoY), and the FY2025 annual result was $3.0 billion, up 45.0% from the prior year.
- Depreciation and Depletion retreated to $581.0 million in Q1 2026 per MRK's latest filing, from $1.5 billion in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $1.5 billion in Q4 2025 and troughed at $1.0 million in Q3 2025.
- A 5-year average of $451.2 million and a median of $448.0 million in 2022 frame the typical range for Depreciation and Depletion.
- On a YoY basis, Depreciation and Depletion climbed as much as 579.1% in 2025 and fell as far as 98.82% in 2025.
- A 5-year view of Depreciation and Depletion shows it stood at $430.0 million in 2022, then climbed by 16.74% to $502.0 million in 2023, then grew by 3.19% to $518.0 million in 2024, then soared by 188.22% to $1.5 billion in 2025, then sank by 61.09% to $581.0 million in 2026.
- Business Quant data shows MRK's Depreciation and Depletion at $581.0 million in Q1 2026, $1.5 billion in Q4 2025, and $1.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 139.00 Mn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 581.00 Mn |
| Mar 31, 2026 | 581.00 Mn |
| Dec 31, 2025 | 1.49 Bn |
| Dec 31, 2025 | 1.49 Bn |
| Sep 30, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 455.00 Mn |
| Jun 30, 2025 | 455.00 Mn |
| Mar 31, 2025 | 502.00 Mn |
| Mar 31, 2025 | 502.00 Mn |
| Dec 31, 2024 | 518.00 Mn |
| Dec 31, 2024 | 518.00 Mn |
| Sep 30, 2024 | 85.00 Mn |
| Sep 30, 2024 | 85.00 Mn |
| Jun 30, 2024 | 67.00 Mn |
| Jun 30, 2024 | 67.00 Mn |
| Mar 31, 2024 | 511.00 Mn |
| Mar 31, 2024 | 511.00 Mn |
| Dec 31, 2023 | 502.00 Mn |
| Dec 31, 2023 | 502.00 Mn |